- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01581346
Exercise Study in Patients With Lung Cancer (POSITIVE)
April 18, 2012 updated by: German Cancer Research Center
Pilot Study to Establish an Exercise Intervention in Patients With Lung Cancer
In the course of their disease patients with Non small cell lung cancer (NSCLC) often experience impaired psychological and physical functioning resulting in a reduced quality of life (QoL).
The aim of the study is to explore the feasibility and the effects of an eight weeks combined muscle strength and endurance training on physical capacity and QoL.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In this open, prospective, single center study 40 patients (pts) with NSCLC undergoing adjuvant or palliative chemo-/ or radiotherapy are enrolled.
Physical status is assessed by using the 6 Minute Walk Test (6MWT) for endurance and by using the Handheld Dynamometer (HHDM) for strength (flexion and extension of elbow, hip and knee).
Psychological performance is measured by standardized questionnaires (MFI, FACT-L, PHQ - 9).
Data are collected at baseline (T0) and after the 8 weeks sports intervention (T1).
Pts are instructed to train at least 5 times/ week in the inpatient setting.
After discharge pts are instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
Feasibility is defined as an adherence of two trainings per week during at least 6 weeks (out of 8 weeks of the intervention).
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Heidelberg, Germany, 69126
- Thoracic Oncology Clinic for Thoracic Diseases
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female patients
- histological confirmed diagnosis of Non small cell lung cancer (NSCLC)
- current treatment: chemo-and/or radiotherapy
- age > 18y
- Body Mass Index (BMI) > 18
- written informed consent
Exclusion Criteria:
- acute infection
- immobility > 2 days
- severe neurological impairment
- severe cardiac impairment
- severe pulmonal impairment
- severe renal impairment
- acute bleedings
- alcohol-/drug-abuse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: exercise intervention
Pts were instructed to train at least 5 times/ week in the inpatient setting.
After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
|
Pts were instructed to train at least 5 times/ week in the inpatient setting.
After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
- number of patients who are adherent to the exercise intervention
Time Frame: 8 months
|
Adherence is defined as: completion of at least two training sessions per week during minimum six weeks out of eight weeks of the intervention.
|
8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
- effects of the exercise intervention on psychological symptoms (e.g. quality of life)
Time Frame: 8 months
|
Quality of life will be measured by the standardized and validated questionnaire FACT-L;
|
8 months
|
|
- effects of the exercise intervention on physical symptoms (muscle strength and endurance)
Time Frame: 8 months
|
Muscle strength will be measured by hand held dynamometry and endurance by 6 Minute Walk Test
|
8 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Thomas, MD, Heidelberg University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (Actual)
October 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
April 5, 2012
First Submitted That Met QC Criteria
April 18, 2012
First Posted (Estimate)
April 20, 2012
Study Record Updates
Last Update Posted (Estimate)
April 20, 2012
Last Update Submitted That Met QC Criteria
April 18, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- POSITIVE_II
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of California, DavisNational Cancer Institute (NCI)RecruitingNon Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IV | Non-small Cell Lung Cancer Stage IIIC | Non-small Cell Lung Cancer UnresectableUnited States
-
Royal Marsden NHS Foundation TrustUniversity of Cambridge; Royal Brompton & Harefield NHS Foundation Trust; Institute... and other collaboratorsRecruitingNon Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Locally Advanced NSCLC - Non-Small Cell Lung Cancer | Oncogene-addicted Non Small Cell Lung Cancer | Early-stage Operable Non Small Cell Lung Cancer | Stage 2/3 Operable Non Small Cell Lung CancerUnited Kingdom
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbTerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
Brigham and Women's HospitalFood and Drug Administration (FDA)Active, not recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Advanced Squamous Non Small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Megan Daly, MDBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on Exercise intervention
-
VA Office of Research and DevelopmentRecruitingMobility Impairment | Asymptomatic Carotid Stenosis (50-69%)United States
-
The Miriam HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of AarhusRecruiting
-
Glasgow Caledonian UniversityUnknown
-
Turku University HospitalUniversity of Turku; University of Helsinki; Academy of Finland; European Foundation... and other collaboratorsUnknownType 2 Diabetes Mellitus | Healthy VolunteersFinland
-
Hacettepe UniversityHacettepe University Scientific Research Projects Coordination UnitNot yet recruitingSubstrate Oxidation | Postprandial Metabolism | Exercise Physiology | Cardiovascular Risk MarkersTurkey (Türkiye)
-
Medipol UniversityCompleted
-
University Medical Center GroningenDutch Kidney Foundation; Innovation Fund of the Dutch Medical Insurance CompaniesCompletedMetabolic Syndrome | Kidney Transplant | Post-transplant Weight GainNetherlands
-
Istanbul UniversityCompletedGlenohumeral ArthritisTurkey
-
Aristotle University Of ThessalonikiCompleted